Steward Partners Investment Advisory’s UroGen Pharma URGN Stock Holding History

Steward Partners Investment Advisory’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-500	Closed	-$4K	–	3389
2022 Q2	$4K	Hold	500	–	–	﹤0.01%	2871
2022 Q1	$4K	Hold	500	–	–	﹤0.01%	2984
2021 Q4	$5K	Hold	500	–	–	﹤0.01%	2846
2021 Q3	$8K	Hold	500	–	–	﹤0.01%	2691
2021 Q2	$8K	Hold	500	–	–	﹤0.01%	6332
2021 Q1	$9.74K	Buy	+500	New	+$10.6K	﹤0.01%	2792
2020 Q4	–	Sell	-300	Closed	-$6K	–	2999
2020 Q3	$6K	Buy	300 +200	+200%	+$4.53K	﹤0.01%	2324
2020 Q2	$3K	Hold	100	–	–	﹤0.01%	2423
2020 Q1	$1K	Hold	100	–	–	﹤0.01%	2433
2019 Q4	$3K	Hold	100	–	–	﹤0.01%	2381
2019 Q3	$2K	Hold	100	–	–	﹤0.01%	2459
2019 Q2	$3K	Buy	+100	New	+$3.69K	﹤0.01%	2385

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Steward Partners Investment Advisory's URGN Position: Q3 2022 in Review

Steward Partners Investment Advisory sold out of UroGen Pharma (URGN) in Q3 2022, closing a stake of 500 shares — an estimated $4K sold.

Steward Partners Investment Advisory first reported a position in URGN in Q2 2019 and held it in 12 quarters. The position peaked at $9.74K in Q1 2021. 60 funds tracked by Wall St. Rank hold URGN as of Q3 2022.

Steward Partners Investment Advisory reported no remaining UroGen Pharma position as of Q3 2022 after selling out during the quarter.
Steward Partners Investment Advisory sold 500 UroGen Pharma shares in Q3 2022, an estimated $4K.
Steward Partners Investment Advisory first reported a position in UroGen Pharma in Q2 2019 and held it in 12 quarters.
Steward Partners Investment Advisory's UroGen Pharma position peaked at $9.74K in Q1 2021.
60 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2022.

Based on Steward Partners Investment Advisory's 13F filing for Q3 2022, filed 10 Nov 2022.